Palatin Technologies (PTN) Stock Price, News & Analysis

Company Overview

Palatin Technologies is a biopharmaceutical company focused on developing medicines that target melanocortin receptors, which are involved in processes such as inflammation, immune response and appetite regulation. Its research has included peptide-based treatments for inflammatory and other medical conditions.

The company is best known for developing bremelanotide, marketed as Vyleesi, which the U.S. Food and Drug Administration approved in 2019 to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. Palatin pursued commercialization through licensing arrangements.

Based in Cranbury, New Jersey, Palatin has conducted research and development in the United States and has worked with commercial partners on its products. Its business centers on advancing and licensing drug candidates rather than operating a broad portfolio of marketed medicines.

Key Stats

• Today's Range: $5.81 to $6.40
• 50-Day Range: $4.77 to $13.36
• 52-Week Range: $4.51 to $31.00
• Volume: 30,103 shs
• Average Volume: 35,502 shs
• Market Capitalization: $11.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.00
• Consensus Rating: Buy

Palatin Technologies Stock Analysis - MarketRank™

Palatin Technologies scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Palatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Palatin Technologies has a consensus price target of $55.00, representing about 782.8% upside from its current price of $6.23.

Amount of Analyst Coverage

Palatin Technologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Palatin Technologies has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PTN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Palatin Technologies does not currently pay a dividend.

Dividend Growth

Palatin Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Palatin Technologies this week, compared to 0 articles on an average week.

Search Interest

Only 2 people have searched for PTN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Palatin Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.10% of the stock of Palatin Technologies is held by insiders.

Percentage Held by Institutions

11.50% of the stock of Palatin Technologies is held by institutions.

Company Calendar

• Last Earnings: 9/28/2026
• Today: 11/15/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:PTN
• CIK: 911216
• Web: palatin.com
• Phone: (609) 495-2200
• Fax: 609-495-2202
• Employees: 25
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Palatin Technologies: $55.00
• High Price Target: $60.00
• Low Price Target: $50.00
• Potential Upside/Downside: +782.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.31 million
• Net Margins: N/A
• Pretax Margin: -48.50%
• Return on Equity: -141.40%
• Return on Assets: -58.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.04
• Quick Ratio: 5.04

Sales & Book Value

• Annual Sales: $4.49 million
• Price / Sales: 2.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.95 per share
• Price / Book: 1.05

Miscellaneous

• Outstanding Shares: 1,780,000
• Free Float: 1,653,000
• Market Cap: $11.09 million
• Optionable: N/A
• Beta: 0.63